Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD74 | P04233 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | KMO | O15229 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.49 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | DDT | P30046 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30425732 | 1.00 | CD74 (0.53) | CD74MIFKMONPC1RAB9A | |
| SCHEMBL27676654 | 0.89 | ATM (0.41) | CD74MIFKMONPC1RAB9A | |
| SCHEMBL5168264 | 0.86 | GRK6 (0.49) | ALDH1A1 | |
| SCHEMBL3065165 | 0.86 | PARP1 (0.46) | MAP2K4MAPK1 | |
| SCHEMBL733156 | 0.84 | DHODH (0.49) | CD74MIFKMONPC1RAB9A | |
| Hydrochloric Acid SCHEMBL12469361 | 0.84 | MAP2K4 (0.45) | MAP2K4MAPK1 | |
| SCHEMBL6175974 | 0.83 | FFAR4 (0.38) | CD74MIFKMONPC1RAB9A | |
| SCHEMBL2513559 | 0.83 | ALOX15 (0.36) | CD74MIFNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1505455 | 0.82 | GABRG2 (0.50) | NPC1RAB9AALDH1A1HPGDCA12 | |
| SCHEMBL13542931 | 0.82 | ACHE (0.38) | CD74MIFNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102503967-B | One class single-substrate white rare earth compound and Synthesis and application thereof | FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER, CHINESE ACADEMY OF SCIENCES (CN) | 2016-03-02 | — | — | CN | claimed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| EP-4192830-A1 | 2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY | Italfarmaco SpA (IT) | 2023-06-14 | — | — | EP | disclosed |
| CN-116157398-A | 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy | 意大发马克股份公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-3350177-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017049068-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| CN-102503967-B | One class single-substrate white rare earth compound and Synthesis and application thereof | FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER, CHINESE ACADEMY OF SCIENCES (CN) | 2016-03-02 | — | — | CN | disclosed |
| CN-102503967-B | One class single-substrate white rare earth compound and Synthesis and application thereof | FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER, CHINESE ACADEMY OF SCIENCES (CN) | 2016-03-02 | — | — | CN | disclosed |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-01-21 | — | — | US | disclosed |
| US-5145765-A | Containing a compound capable of releasing a development inhibitor by oxidation and a hydrazide compound | FUJI PHOTO FILM CO., LTD. (JP) | 1992-09-08 | — | — | US | disclosed |
| US-5132201-A | Silver halide photographic material with redox releaser | FUJI PHOTO FILM CO., LTD. (JP) | 1992-07-21 | — | — | US | disclosed |
| US-5124231-A | Mixture of hydrazine derivative, redox compound, and melting point lowering agent | FUJI PHOTO FILM CO., LTD. (JP) | 1992-06-23 | — | — | US | disclosed |
| US-5085971-A | Redox system capable of releasing development inhibitor by oxidation and a hydrazine compound | FUJI PHOTO FILM CO., LTD. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0442323-A2 | Silver halide color reversal photographic material capable of providing interimage effect | FUJI PHOTO FILM CO., LTD. (JP) | 1991-08-21 | — | — | EP | disclosed |
| EP-0436027-A1 | METHOD OF TREATING SILVER HALIDE PHOTOGRAPHIC MATERIAL | FUJI PHOTO FILM CO., LTD. (JP) | 1991-07-10 | — | — | EP | disclosed |
| US-5006444-A | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1991-04-09 | — | — | US | disclosed |
| EP-0420005-A1 | high contrast silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1991-04-03 | — | — | EP | disclosed |
| EP-0398285-A2 | Silver halide photographic materials | FUJI PHOTO FILM CO., LTD. (JP) | 1990-11-22 | — | — | EP | disclosed |
| EP-0395069-A2 | Silver halide photographic materials | FUJI PHOTO FILM CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | CD74 830/4885MIF 1358/4885KMO 495/4885 |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | CD74 1040/4885MIF 984/4885KMO 546/4885 |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | CD74 2248/4885MIF 2725/4885KMO 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.